It can be difficult and expensive to determine potential vaccine/drug targets. There are limited tools to determine immunology markers in our efforts to develop a vaccine for HIV and Malaria.
To identify new antigens for vaccine development and new antibodies for prophylactic or therapeutic. We aim to leverage a new technology that would provide critical information in a matter of weeks/months as opposed to years with alternative technologies.
Early stage company that is leveraging a technology spin-out from Stanford
Foundation focus: To validate the potential technology in order to help accelerate the availability of information that determines strong vaccine candidates
Unsecured convertible note
Date: June 2012
Associated funding: Three grants focused on malaria or HIV related technology